COTELLIC

Peak

cobimetinib

Roche

NDAORALTABLETPriority Review

Approved

Nov 2015

Lifecycle

Peak

Competitive Pressure

0/100

Clinical Trials

Mechanism of Action

mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase 1 (MEK1) and MEK2. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E and K mutations result in constitutive activation of the…

Indications (4)

metastatic melanoma with a BRAF V600E V600K mutation combination with vemurafenib melanoma

Clinical Trials (5)

NCT05768178Phase 2/3Recruiting

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Started Mar 2023

30 enrolled

Haematological MalignancyMelanomaThyroid Cancer, Papillary+9 more

NCT05034627Phase 1Active Not Recruiting

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Started Aug 2022

15 enrolled

Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaStage II Pancreatic Cancer AJCC v8+4 more

NCT05125471Phase 2Completed

Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)

Started Jul 2022

3 enrolled

Arteriovenous Malformations (Extracranial)

NCT04835805Phase 1Active Not Recruiting

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Started May 2021

65 enrolled

Melanoma

NCT04079179Phase 2Recruiting

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Started Apr 2021

90 enrolled

Langerhan's Cell HistiocytosisJuvenile XanthogranulomaErdheim-Chester Disease+4 more